Demonstrating bioequivalence of locally acting orally inhaled drug products (OIPs): Workshop summary report

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 23, Issue 1, 2010, Pages 1-29

  Adams, Wallace P ^a   Ahrens, Richard C ^b   Chen, Mei Ling ^a   Christopher, David ^c   Chowdhury, Badrul A ^a   Conner, Dale P ^a   Dalby, Richard ^d   Fitzgerald, Kevin ^e   Hendeles, Leslie ^f   Hickey, Anthony J ^g   Hochhaus, Günther ^h   Laube, Beth L ⁱ   Lucas, Paul ^j   Lee, Sau L ^a   Lyapustina, Svetlana ^k   Li, Bing ^a   O'Connor, Dennis ^l   Parikh, Neil ^m   Parkins, David A ⁿ   Peri, Prasad ^a   Pitcairn, Gary R ^j   Riebe, Michael ^c   Roy, Partha ^a   Shah, Tushar ^o   Singh, Gur Jai Pal ^p   Sharp, Sandra Suarez ^a   Suman, Julie D ^q   Weda, Marjolein ^r   Woodcock, Janet ^a   Yu, Lawrence ^a   more..

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e GLAXOSMITHKLINE   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h UNIVERSITY OF FLORIDA HEALTH   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^k IPAC RS   (United States)

^l BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^m Axar Pharmaceuticals   (United States)

ⁿ GLAXOSMITHKLINE   (United Kingdom)

^o TEVA PHARMACEUTICALS   (Israel)

^p Watson   (United States)

^q Next Breath LLC   (United States)

^r NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; MOMETASONE FUROATE; NITRIC OXIDE; SALBUTAMOL; SALMETEROL;

AREA UNDER THE CURVE; ASTHMA; BIOEQUIVALENCE; CONFERENCE PAPER; DEVICE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; FOOD AND DRUG ADMINISTRATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; PARTICLE SIZE;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; AEROSOLS; HUMANS; THERAPEUTIC EQUIVALENCY;

EID: 76649105779     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2009.0803     Document Type: Conference Paper

References (97)

1. U.S. Department of Health andHumanSevices (DHHS), Food and Drug Administration (FDA): Innovation or Stagnation. March 2004. Available at: http://www.fda.gov//downloads// ScienceResearch//SpecialTopics// CriticalPathInitiative//Critical PathOpportunitiesReports//ucm113411.pdf
2. DHHS, Center for Drug Evaluation and Research (CDER), FDA, Office of Pharmaceutical Science (OPS), Office of Generic Drugs (OGD): Critical Path Opportunities for Generic Drugs. 1 May 2007. Available at: http://www.fda.gov// ScienceResearch//SpecialTopics//CriticalPathInitiative//Critical Path OpportunitiesReports//ucm077250.htm
3. DeLuca PP, and Lyapustina S: Product quality research institute reports. AAPS PharmSciTech. 2007;8:Article 6.
4. Adams WP, Christopher D, Lee DS, Morgan B, Pan Z, Singh GJP, Tsong Y, and Lyapustina S: Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols, Part 1: background for a statistical method. AAPS PharmSciTech. 2007;8:Article 4.
5. Christopher D, Adams WP, Lee DS, Morgan B, Pan Z, Singh GJP, Tsong Y, and Lyapustina S: Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols: part 2-evaluation of a method for determining equivalence. AAPS PharmSciTech. 2007;8:Article 5.
6. Christopher D, Adams W, Amann A, Bertha C, Byron PR, Doub W, Dunbar C, Hauck W, Lyapustina S, Mitchell J, Morgan B, Nichols S, Pan Z, Singh GJP, Tougas T, Tsong Y, Wolff R, and Wyka B: Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols, Part 3: final report on a statistical procedure for determining equivalence.AAPS PharmSciTech. 2007;8:Article 90.
7. Creticos PS, Adams WP, Petty BG, Lewis LD, Singh GJP, Khattignavong AP, Molzon JA, Martinez MN, Lietman PS, and Williams RL: A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered-dose inhalers. J Allergy Clin Immunol. 2002;110:713-720.
8. Chervinsky P, van As A, Bronsky EA, Dockhorn R, Noonan M, LaForce C, and Pleskow W: Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol. 1994;94:676-683.
9. Kharitonov SA, Yates D, Robbins RA, Logan-Sinclair R, Shinebourne EA, and Barnes PJ: Increased nitric oxide in exhaled air of asthmatic patients. Lancet. 1994;343:133-135.
10. Silkoff PE, McClean P, Spino M, Erlich L, Slutsky AS, and Zamel N: Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. Chest. 2001; 119:1322-1328.
11. Currie GP, Bates CE, Lee DKC, Jackson CM, and Lipworth BJ: Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur J Clin Pharmacol. 2003;59:11-15.
12. Silkoff PE, McClean PA, Slutsky AS, Caramori M, Chapman KR, Gutierrez C, and Zamel N: Exhaled nitric oxide and bronchial reactivity during and after inhaled beclomethasone in mild asthma. J Asthma. 1998;35:473-479.
13. Beck-Ripp J, Griese M, Arenz S, Köring C, Pasqualoni B, and Bufler P: Changes of exhaled nitric oxide during steroid treatment of childhood asthma. Eur Respir J. 2002;19:1015-1019.
14. American Thoracic Society: ATS//ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Resp Crit Care Med. 2005;171:912-930.
15. Chowdhury BA: Exhaled Nitric Oxide Model for Inhaled Corticosteroid Dose-Response. Topic 3: Use of Inhaled Corticosteroid Dose Response as a Means to Establish Bioequivalence of Inhalation Drug Products. FDA//CDER//Advisory Committee for Pharmaceutical Science and Clinical Pharmacology. Rockville, MD, July 23, 2008.
16. Adams WP: Asthma Stability Model For Inhaled Corticosteroid Dose-Response. Topic 3: Use of Inhaled Corticosteroid Dose Response as a Means to Establish Bioequivalence of Inhalation Drug Products. FDA//CDER//Advisory Committee for Pharmaceutical Science and Clinical Pharmacology. Rockville, MD, July 23, 2008.
17. Ahrens RC, Teresi ME, Han S-H, Donnell D, Vanden Burgt JA, and Lux CR: Asthma stability after oral prednisone-a clinical model for comparing inhaled steroid potency. Am J Respir Crit Care Med. 2001;164:1138-1145.
18. Crowder TM, Hickey AJ, Louey MD, and Orr N: A Guide to Pharmaceutical Particulate Science. Interpharm//CRC Press, Boca Raton, FL, p. 205, 2003.
19. WC Hinds: Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles, 2nd ed. Wiley, New York; 1999, chap 11.
20. Sbirlea-Apiou G, Caillibotte G, Yang Y, Katz I, and Martonen T: Deposition mechanics of pharmaceutical particles in human airways. In: AJ Hickey (ed). Inhalation Aerosols: Physical and Biological Basis for Therapy, Informa Healthcare, New York; 2007, chap 1.
21. Olsson B, and Asking L: Critical aspects of the function of inspiratory flow driven inhalers. J Aerosol Med. 1994; 7(Suppl 1):S43-S47.
22. Newman SP, and Chan H-K: In vitro//in vivo comparisons in pulmonary drug delivery. J Aerosol Med Pulm Drug Deliv. 2008;21:77-84.
23. Apiou-Sbirlea G, Simoes-Pichelin M, Caillibotte G, Katz I, Texereau J, Fleming J, Conway J, Scheuch G, and Martonen T: Validated three dimensional CFD modeling of aerosol drug deposition in humans-influence of disease and breathing regimes. In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds). Respiratory Drug Delivery 2008, Book 1. Davis Healthcare, River Grove, IL; pp. 185-195, 2008.
24. Daley-Yates PT, Parkins DA, Thomas MJ, Gillett B, House, KW, and Ortega HG: Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 mg and fluticasone propionate 250 mg: implications for establishing bioequivalence of inhaled products. Clin Ther. 2009;31:370-385.
25. Lin T-C, Breysse PN, Laube BL, and Swift DL: Mouthpiece diameter affects deposition efficiency in cast models of the human oral airways. J Aerosol Med. 2001;14:335-341.
26. Fink JB, and Rubin BK: Problems with inhaler use: A call for improved clinician and patient education. Respir Care. 2005;50:1360-1374.
27. Molimard M, Raherison C, Lignot,S, Depont F, Abouelfath A, and Moore N: Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2003;16:249-254.
28. Khassawneh BY, Al-Ali MK, Alzoubi KH, Batarseh MZ, Al- Safi SA, Sharara AM, and Alnasr HM: Handling of inhaler devices in actual pulmonary practice: Metered-dose inhaler versus dry powder inhalers. Respir Care. 2008;53:324-328.
29. Melani AS: Inhalatory therapy training: a priority challenge for the physician. Acta Biomed. 2007;78:233-245.
30. European Medicines Agency (EMEA): Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. 22 January 2009. Available at: http://www.emea.europa.eu//pdfs// human//ewp//415100enfin.pdf
31. European Medicines Agency (EMEA): Points to consider on the requirements for clinical documentation for orally inhaled products (OIP). 22 April 2004.
32. Health Canada: Guidance to establish equivalence or relative potency of safety and efficacy of a second entry short-acting beta2-agonist metered dose inhaler. February, 1999. Available at: http://www.hc-sc.gc.ca//dhp-mps//alt- formats//hpfb-dgpsa//pdf//prodpharma//mdi-bad-eng.pdf
33. Health Canada: Draft guidance. Submission requirements for subsequent market entry inhaled corticosteroid products for use in the treatment of asthma. August, 2007. Available at: http://www.hc-sc.gc.ca//dhp-mps//alt-formats//hpfb- dgpsa//pdf//prodpharma//inhal-corticost-eng.pdf
34. Chowdhury B: US perspectives on the equivalence of ICS. In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds). Respiratory Drug Delivery 2008, Book 1. Davis Healthcare International Publishing, River Grove, IL; pp. 148-150, 2008.
35. Finney DJ: Statistical Method in Biological Assay, 3rd ed. Charles Griffin & Co, London; pp. 1-12, 1978.
36. Becker AB, and Simons FE: Formoterol, a new long-acting selective b2-agonist, decreases airway responsiveness in children with asthma. Lung. 1990;168(Suppl):99-102.
37. Lipworth B, Tan S, Devlin M, Aiken T, Baker R, and Hendrick D: Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med. 1998;104:431-438.
38. Ahrens RC, Hendeles L, Clarke WR, Dockhorn RJ, Hill MR, Vaughan LM, Lux C, and Han S-H: Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler: a bioassay using methacholine. Am J Respir Crit Care Med. 1999;160:1238-1243.
39. Parameswaran KN, Inman MD, Ekholm BP, Morris MM, Summers E, O'Byrne PM, and Hargreave FE: Protection against methacholine bronchoconstriction to assess relative potency of inhaled b2-agonist. Am J Respir Crit Care Med. 1999;160:354-357.
40. Stewart BA, Ahrens RC, Carrier S, Frosolono M, Lux C, Han S-H, and Milavetz G: Demonstration of in vivo bioequivalence of a generic albuterol metered-dose inhaler to Ventolin. Chest. 2000;117:714-721.
41. Ringdal N, Derom E, Wå hlin-Boll E, and Pauwels R: Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respir Med. 1998;92:1017-1021.
42. Maesen FPV, Costongs R, Smeets SJ, Zweers GMA, and Goedhart DM: Formoterol as dry powder inhalation: a dose finding study in comparison with formoterol metered dose inhaler and placebo. Chest. 1992;101:1376-1381.
43. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, and Lotvall J: Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J. 1997;10:2484-2489.
44. Bousquet J, Huchon G, Leclerc V, Vicaut E, and Lefrançois G: A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients. Respiration. 2005; 72(Suppl 1):6-12.
45. Pohunek P, Matulka M, Rybnícek O, Kopriva F, Honomichlova ́ H, and Svobodová T : Dose-related efficacy and safety of formoterol (Oxis) Turbuhaler- compared with salmeterol Diskhaler in children with asthma. Pediatr Allergy Immunol. 2004;15:32-39.
46. Pauwels RA, Löfdahl C-G, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, and Ullman A: Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337:1405-1411.
47. Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden Burgt J, Donnell D, Hannon S, and Colice GL: Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol. 1999;104:1215-1222.
48. Jatakanon A, Kharitonov S, Lim S, and Barnes PJ: Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax. 1999; 54:108-114. (Pubitemid 29101352)
49. Kelly MM, Leigh R, Jayaram L, Goldsmith CH, Parameswaran K, and Hargreave FE: Eosinophilic bronchitis in asthma: a model for establishing dose-response and relative potency of inhaled corticosteroids. J Allergy Clin Immunol. 2006;117:989-994.
50. Jones SL, Herbison P, Cowan JO, Flannery EM, Hancox RJ, McLachlan CR, and Taylor DR: Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid: dose- response relationship. Eur Respir J. 2002;20:601-608.
51. Kharitonov SA, Donnelly LE, Montuschi P, Corradi M, Collins JV, and Barnes PJ: Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. Thorax. 2002;57:889-896.
52. Woodcock J: The concept of pharmaceutical quality. Am Pharm Rev. 2004;7:10-15.
53. DHHS, FDA, CDER, Center for Biologics Evaluation and Research (CBER): June 2009. Guidance for Industry: Q8(R1) Pharmaceutical Development. Available at: http://www.fda .gov//downloads//Drugs//GuidanceComplianceRegulatory Information//Guidances//ucm073507.pdf
54. Yu LX: Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 2008;25:781-791.
55. DHHS, FDA, CDER: October 1998. Draft Guidance for Industry: Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products: Chemistry, Manufacturing, and Controls Documentation. Available at: http://www.fda .gov//downloads//Drugs//GuidanceComplianceRegulatory Information//Guidances// ucm070573.pdf
56. DHHS, FDA, CDER: April 2003. Draft Guidance for Industry: Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action. Available at: http://www.fda.gov//downloads//Drugs//GuidanceCompliance RegulatoryInformation//Guidances//ucm070111.pdf
57. DHHS, FDA, CDER: 11 April 2003. Statistical Information from the June 1999 Draft Guidance and Statistical Information for In Vitro Bioequivalence Data Posted on August 18, 1999. Available at: http://www.fda.gov//downloads//Drugs// GuidanceComplianceRegulatoryInformation//Guidances// ucm070118.pdf
58. Advair Diskus labeling: April 2008, GlaxoSmithKline, Research Triangle Park, NC. Available at: http://www.advair. com//index.html
59. Chapter : Aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers U.S. Pharmacopeia 32//National Formulary 27, United States Pharmacopeial Convention, Rockville, MD, 2009.
60. Chavan V, and Dalby R: Effect of rate of rise in simulated inspiratory air flow on dry powder inhaler (DPI) performance. In: RN Dalby, PR Byron, SJ Farr, and J Peart (eds). Respiratory Drug Delivery VII, Vol II. Serentec Press, Raleigh, NC; pp. 593-596, 2000.
61. Bagger-Jorgensen H, Sandell D, Lundback H, and Sundahl M: Effect of inherent variability of inhalation products on impactor mass balance limits. J Aerosol Med. 2005;18:367-378.
62. O'Connor D, Tougas T, Patel R, Davidson W, and Carr D: The discriminatory nature of the spray pattern test. AAPS J 2005;7(Suppl 2):Abstract 668.
63. DHHS, FDA, CDER: July 2002. Guidance for Industry: Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products-Chemistry, Manufacturing, and Controls Documentation. Available at: http://www.fda.gov// downloads//Drugs// GuidanceComplianceRegulatoryInformation//Guidances//ucm 070575.pdf
64. Guo C, Ye W, Kauffman J, and Doub WH: Evaluation of impaction force of nasal sprays and metered-dose inhalers using the texture analyser. J Pharm Sci. 2008;98:2799-2806.
65. DHHS, FDA, CDER: Approved Drug Products with Therapeutic Equivalence Evaluations (''Orange Book''), 29th ed, 2009, Therapeutic equivalence-related terms, pp. vi-viii. Available at: http://www.fda.gov//downloads//Drugs// DevelopmentApprovalProcess//UCM071436.pdf
66. Biomarkers Definitions Working Group: Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95.
67. DHHS, FDA, CDER: 2 June 1995, Guidance: Topical Dermatologic Corticosteroids: In Vivo Bioequivalence. Available at: http://www.fda.gov// downloads//Drugs//Guidance ComplianceRegulatoryInformation//Guidances// ucm070234. pdf
68. Cockcroft DW, Killian DN, Mellon JJA, and Hargreave FE: Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy. 1977;7:235-243.
69. Geoffroy P, Lalonde RL, Ahrens R, Clarke W, Hill MR, Vaughan LM, and Grossman J: Clinical comparability of albuterol delivered by the breath-actuated inhaler (Spiros) and albuterol by MDI in patients with asthma. Ann Allergy Asthma Immunol. 1999;82:377-382.
70. Derom EY, Pauwels RA, and Van Der Straeten MEF: the effect of inhaled salmeterol on methacholine responsiveness in subjects with asthma up to 12 hours. J Allergy Clin Immunol. 1992;89:811-815.
71. Ahrens RC, Teresi ME, Han S-H, Donnell D, Vanden Burgt JA, and Lux CR: Asthma stability after oral prednisone: a clinical model for comparing inhaled steroid potency. Am J Respir Crit Care Med. 2001;164:1138-1145.
72. Ahrens RC, Hendeles L, Teresi ME, Lux CR, Vanden Burgt J, Hart KA, and Ekholm BP: Stability of asthma following maximization of lung function with a high-dose inhaled corticosteroid (ICS) burst: a more precise method for comparing clinical potency of ICS. J Aerosol Med. 2003; 16:197.
73. Fuglsang A, Leach C, and Mayers I: Therapeutic equivalence of inhaled corticosteroids-workshop on regional differences in regulatory requirements. In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds). Respiratory Drug Delivery 2008, Book 1. Davis Healthcare, River Grove, IL; pp. 133-147, 2008.
74. Lipworth BJ, Sims EJ, Das SK, Buck H, and Paterson M: Dose-response comparison of budesonide dry powder inhalers using adenosine monophosphate bronchial challenge. Ann Allergy Asthma Immunol. 2005;94:675-681.
75. Ahrens RC: Proving inhaled corticosteroid equivalence: what are the clinically acceptable differences in performance? In: RN Dalby, PR Byron, J Peart, JD Suman, SJ Farr, and PM Young (eds). Respiratory Drug Delivery 2008, Book 1. Davis Healthcare, River Grove, IL, 2008, pp. 101-108.
76. Newman SP, and Pitcairn GR: Gamma scintigraphy and SPECT. In: G Lappin G, and S Temple, (eds). Radiotracers in Drug Development. CRC Press, Boca Raton, FL; chap 12, 2006.
77. Newman SP, Pitcairn GR, Hirst PH, and Rankin L: Radionuclide imaging technologies and their use in evaluating asthma drug deposition in the lungs. Adv Drug Deliv Rev. 2003;55:851-867.
78. Newman SP, Hirst PH, Pitcairn GR, and Clark AR: Understanding regional lung deposition data in gamma scintigrapy. In: RN Dalby, PR Byron, and SJ Farr SJ, (eds). Respiratory Drug Delivery VI. Interpharm Press, Buffalo Grove, IL; pp. 9-15, 1998.
79. Pitcairn GR, and Newman SP: Radiolabelling of dry powder formulations. In: RN Dalby, PR Byron, and SJ Farr, (eds). Respiratory Drug Delivery VI. Interpharm Press, Buffalo Grove, IL; pp. 397-399, 1998.
80. Snell NJC, and Ganderton D: Assessing lung deposition of inhaled medications. Respir Med. 1999;93:123-133.
81. Singh GJP, and Adams WP: US regulatory and scientific considerations for approval of generic locally acting orally inhaled and nasal drug products. In: RN Dalby, PR Byron, J Peart, and JD Suman, (eds). Respiratory Drug Delivery Europe 2005. Davis Healthcare, River Grove, IL; pp. 115-125, 2005.
82. Chowdhury BA: The regulatory demands of clinical testing protocols for powder inhalers in the USA. In: RN Dalby, PR Byron, J Peart, and JD Suman (eds). Respiratory Drug Delivery Europe 2007. Davis Healthcare, River Grove, IL; pp. 101-107, 2007.
83. Hochhaus G: Bioequivalence of inhaled corticosteroids-with emphasis on pharmacokinetic tools. In: PQRI Workshop on Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products. Bethesda, MD, March 9-10, 2009. Available at: http://www.pqri.org//workshops//Bioequiv//imagespdfs//final// Hochhaus-final.pdf
84. Borgström L, and Nilsson M: A method for determination of the absolute pulmonary availability of inhaled drugs: Terbutaline. Pharm. Res. 1990;7:1068-1070.
85. Thorsson L, Edsbäcker S, and Conradson T-B: Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994; 7:1839-1844.
86. Thorsson L, and Edsbacker S: Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. Eur Respir J.1998;12:1340-1345.
87. Bennett JA, Harrison TW, and Tattersfield AE: The contribution of the swallowed fraction of an inhaled dose of salmeterol to its systemic effects. Eur Respir J. 1999;13: 445-448.
88. Ward JK, Dow J, Dallow N, Eynott P, Milleri S, and Ventresca GP. Enantiomeric disposition of inhaled, intravenous and oral racemic-salbutamol in man-no evidence of enantioselective lung metabolism. Br J Clin Pharmacol 2000; 49:15-22.
89. Silkstone VL, Corlett SA, and Chrystyn H: Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization. Br J Clin Pharmacol. 2002;54:115-119.
90. Singh G. Agenda Item: Bioequivalence of Albuterol MDIs. Joint Meeting of the Advisory Committee for Pharmaceutical Science and the Pulmonary-Allergy Drugs Advisory Committee. FDA, Gaithersburg, MD. 16 August 1996, Transcript, pp. 53-68.
91. Chowdhury BA: The FDA critical path initiative: clinical considerations for demonstration of dose-response for inhaled corticosteroids-exhaled nitric oxide model. In: PQRI Workshop on Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products, Bethesda, MD, March 9-10, 2009. Available at: http://www.pqri.org//workshops//Bioequiv//imagespdfs//final// Chowdhury-9Mar09-PQRI.pdf
92. Joint Statement of the American Thoracic Society and the European Respiratory Society: ATS//ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. 2005. Am J Respir Crit Care Med. 2005;171: 912-930.
93. Silkoff PE, Carlson M, Bourke T, Katial R, Ogren E, and Szefler SJ: The aerocrine exhaled nitric oxide monitoring system NIOX is cleared by the US Food and Drug Administration for monitoring therapy in asthma. J Allergy Clin Immunol. 2004;114:1241-1256.
94. Tarsin W, Assi KH, and Chrystyn H: In-vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler. J Aerosol Med. 2004;17:25-32.
95. Richards R, Simpson SF, Renwick AG, and Holgate ST: Inhalation rate of sodium cromoglycate determines plasma pharmacokinetics and protection against AMP-induced bronchoconstriction in asthma. Eur Respir J. 1988;1:896-901.
96. Pedersen S, Hansen OR, and Fuglsang G: Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child. 1990;65:308-310.
97. Engel T, Scharling B, Skovsted B, and Heinig JH: Effects, side effects and plasma concentrations of turbutaline in adult asthmatics after inhaling from a dry powder inhaler device at different inhalation flows and volumes. Br J Clin Pharmacol. 1992;33:439-444.